Appendix
- Home
- Cancer Infomation
Etiology & Risk Factors
Appendiceal cancer is a rare and heterogeneous group of malignancies, representing approximately 1% of all gastrointestinal tumors. Pathogenesis varies significantly by histologic subtype.
Environmental/Lifestyle Triggers
-
Traditional lifestyle factors (diet, smoking) are less clearly linked.
Chronic inflammation (e.g., in the setting of ulcerative colitis) and female sex (possibly due to increased incidental detection during gynecological procedures) are established risk factors.
Genetic Predispositions & Mutations
- Mucinous Pathway: Characterized by a high frequency of GNAS (up to 70%) and KRAS mutations. GNAS mutations are particularly pathognomonic for mucinous differentiation and PMP.
- Adenocarcinoma Pathway: Frequently involves TP53, APC, and SMAD4 mutations, mirroring the colorectal "adenoma-to-carcinoma" sequence.
- Microsatellite Instability (MSI): While most are Microsatellite Stable (MSS), approximately 3–5% exhibit MSI-H/dMMR, which is a critical marker for immunotherapy eligibility.
Primary Subtypes
- Appendiceal Neuroendocrine Tumors (ANETs): The most common subtype, typically well-differentiated.
- Mucinous Neoplasms: Including Low-grade Appendiceal Mucinous Neoplasm (LAMN) and High-grade (HAMN). These are the primary drivers of Pseudomyxoma Peritonei (PMP).
- Appendiceal Adenocarcinoma: Colonic-type (non-mucinous) and mucinous adenocarcinoma.
- Goblet Cell Adenocarcinoma (GCA): A unique, aggressive entity with both neuroendocrine and exocrine features.
Clinical Manifestations (Symptoms)
Symptoms are frequently obscured by the organ’s small size, often leading to incidental diagnosis.
Early-Stage:
- Acute Appendicitis: Up to 30–50% of appendiceal cancers are discovered incidentally during pathology review following an appendectomy for suspected appendicitis.
- Vague, persistent right lower quadrant (RLQ) discomfort.
Advanced-Stage:
- Increased Abdominal Girth: Often the first sign of PMP ("jelly belly") due to mucinous ascites.
- Palpable Mass: In the RLQ or pelvis (Krukenberg tumor in females).
- Incisional Hernia: Mucinous deposits may first manifest as a mass within a prior surgical scar.
Paraneoplastic Syndromes
- Carcinoid Syndrome: Rare in localized ANETs; typically only with extensive liver metastasis. Symptoms include episodic flushing, secretory diarrhea, and bronchospasm.
- Hypercalcemia: Occasionally seen in aggressive adenocarcinomas due to PTHrP secretion.
Diagnostic Workup
The gold standard for diagnosis is histopathologic examination of the appendix.
Biomarker & Molecular Testing
- Tumor Markers: Baseline CEA, CA 19-9, and CA-125 are done. While not diagnostic, they are essential for longitudinal monitoring.
- Comprehensive Genomic Profiling (CGP): Mandated for Stage IV disease to identify KRAS, GNAS, BRAF, and HER2 alterations.
- Liquid Biopsy (ctDNA): tissue-free ctDNA monitoring is used to detect molecular recurrence following radical surgery.
Common Investigations & Staging
Staged using multiphase CT to calculate the PCI, diffusion-weighted MRI to detect small peritoneal deposits, and PET-CT for high-grade tumors.
- CT Abdomen/Pelvis (Multiphase): Rationale is to calculate the Peritoneal Carcinomatosis Index (PCI). CT is the most used modality for initial staging.
- MRI with Diffusion-Weighted Imaging (DWI): Superior to CT for detecting small-volume peritoneal deposits in the small bowel mesentery.
- PET-CT: Generally not used for low-grade mucinous tumors (which are FDG-cold) but valuable for staging high-grade adenocarcinomas or GCAs to rule out extra-abdominal metastasis.
Treatment Overview
Treatment is highly individualized based on the histologic grade and the presence of peritoneal dissemination.
1. Surgery
- Simple Appendectomy: Often sufficient for ANETs very small sized at the tip and LAMN with negative margins.
- Right Hemicolectomy: Indicated for ANETs, GCA, or high-grade adenocarcinoma to ensure adequate lymphadenectomy.
- CRS + HIPEC: The cornerstone of curative intent for PMP disease.
- Cytoreductive Surgery (CRS): Radical removal of all visible peritoneal disease.
- HIPEC: Intraoperative perfusion of heated chemotherapy (Mitomycin-C or Oxaliplatin) to treat microscopic residual disease.
2. Systemic Therapy
- Chemotherapy: Regimens follow colorectal protocols (e.g., FOLFOX or CAPOX).
- Targeted Therapy: Cetuximab/Panitumumab for RAS wild-type non-mucinous tumors.
- Immunotherapy: Nivolumab/Ipilimumab for MSI-H/dMMR subsets.
Emerging Therapies
- Adjuvant De-escalation: Data from ASCO GI 2026 indicates that Stage II/III low-grade appendiceal cancers may not benefit from adjuvant systemic chemotherapy following R0 resection, shifting the focus toward surveillance-only protocols.
- PI3K/mTOR Inhibitors: Showing efficacy in $GNAS$-mutated mucinous tumors, which often lack other actionable targets.
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Utilized for patients with high-volume peritoneal disease who are not yet candidates for CRS+HIPEC, used as a neoadjuvant "conversion" therapy.
Medical Disclaimer
This information is provided for professional educational purposes and does not replace institutional clinical guidelines.
Appendix cancer management should be conducted at high-volume peritoneal surface malignancy centers.